Skip to main content Accessibility help
×
Home

Risk Factors for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-Analysis

  • Abhishek Deshpande (a1) (a2), Vinay Pasupuleti (a3), Priyaleela Thota (a3), Chaitanya Pant (a4), David D.K. Rolston (a5), Adrian V. Hernandez (a6) (a7), Curtis J. Donskey (a3) (a8) and Thomas G. Fraser (a2)...

Abstract

OBJECTIVE

An estimated 20–30% of patients with primary Clostridium difficile infection (CDI) develop recurrent CDI (rCDI) within 2 weeks of completion of therapy. While the actual mechanism of recurrence remains unknown, a variety of risk factors have been suggested and studied. The aim of this systematic review and meta-analysis was to evaluate current evidence on the risk factors for rCDI.

DESIGN

We searched MEDLINE and 5 other databases for subject headings and text related to rCDI. All studies investigating risk factors of rCDI in a multivariate model were eligible. Information on study design, patient population, and assessed risk factors were collected. Data were combined using a random-effects model and pooled relative risk ratios (RRs) were calculated.

RESULTS

A total of 33 studies (n=18,530) met the inclusion criteria. The most frequent independent risk factors associated with rCDI were age≥65 years (risk ratio [RR], 1.63; 95% confidence interval [CI], 1.24–2.14; P=.0005), additional antibiotics during follow-up (RR, 1.76; 95% CI, 1.52–2.05; P<.00001), use of proton-pump inhibitors (PPIs) (RR, 1.58; 95% CI, 1.13–2.21; P=.008), and renal insufficiency (RR, 1.59; 95% CI, 1.14–2.23; P=.007). The risk was also greater in patients previously on fluoroquinolones (RR, 1.42; 95% CI, 1.28–1.57; P<.00001).

CONCLUSIONS

Multiple risk factors are associated with the development of rCDI. Identification of modifiable risk factors and judicious use of antibiotics and PPI can play an important role in the prevention of rCDI.

Infect Control Hosp Epidemiol 2015;00(0): 1–9

Copyright

Corresponding author

Address correspondence to Abhishek Deshpande MD, PhD, Assistant Staff in Medicine Institute Center for Value Based Care, Cleveland Clinic, 9500 Euclid Avenue, Desk G1-40, Cleveland OH 44195 (abhishekdp@gmail.com).

Footnotes

Hide All
*

Contributed equally to this study.

Footnotes

References

Hide All
1. Louie, TJ, Miller, MA, Mullane, KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. New Engl J Med 2011;364:422431.
2. Johnson, S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009;58:403410.
3. Pepin, J, Routhier, S, Gagnon, S, Brazeau, I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006;42:758764.
4. Kelly, CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 2012;18(Suppl 6):2127.
5. Abou Chakra, CN, Pepin, J, Sirard, S, Valiquette, L. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PloS One 2014;9:e98400.
6. Garey, KW, Sethi, S, Yadav, Y, DuPont, HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008;70:298304.
7. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
8. Peduzzi, P, Concato, J, Kemper, E, Holford, TR, Feinstein, AR. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996;49:13731379.
9. Wells, GA, Shea, B, O’Connell, D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Published 2000. Accessed April 30, 2014.
10. DerSimonian, R, Laird, N. Meta-analysis in clinical trials. Controlled Clin Trial 1986;7:177188.
11. Kwok, CS, Arthur, AK, Anibueze, CI, Singh, S, Cavallazzi, R, Loke, YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107:10111019.
12. Zhang, J, Kai, FY. What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:16901691.
13. Higgins, JP, Thompson, SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:15391558.
14. Deeks, JJ, Higgins, JPT, Altman, DG. Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions. Hoboken, NJ: John Wiley & Sons, Ltd;, 2008, pp. 243296.
15. Egger, M, Davey Smith, G, Schneider, M, Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629634.
16. Duval, S, Tweedie, R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455463.
17. Peterfreund, GL, Vandivier, LE, Sinha, R, et al. Succession in the gut microbiome following antibiotic and antibody therapies for Clostridium difficile . PloS One 2012;7:e46966.
18. Kanno, T, Matsuki, T, Oka, M, et al. Gastric acid reduction leads to an alteration in lower intestinal microflora. Biochem Biophys Res Comm 2009;381:666670.
19. Muto, CA, Pokrywka, M, Shutt, K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hospital Epidemiol 2005;26:273280.
20. Fekety, R, McFarland, LV, Surawicz, CM, Greenberg, RN, Elmer, GW, Mulligan, ME. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997;24:324333.
21. Do, AN, Fridkin, SK, Yechouron, A, et al. Risk factors for early recurrent Clostridium difficile-associated diarrhea. Clin Infect Dis 1998;26:954959.
22. McFarland, LV, Surawicz, CM, Rubin, M, Fekety, R, Elmer, GW, Greenberg, RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hospital Epidemiol 1999;20:4350.
23. Kyne, L, Warny, M, Qamar, A, Kelly, CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001;357:189193.
24. de Isusi, AM, Gonzalez, E, Gayoso, P, Gastelu-Iturri, J, Barbeito, L, Fernandez, R. Diarrhea associated with Clostridium difficile: experience at a secondary hospital. Medicina clinica 2003;121:331333.
25. Pepin, J, Alary, ME, Valiquette, L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005;40:15911597.
26. Linsky, A, Gupta, K, Lawler, EV, Fonda, JR, Hermos, JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection. Arch Intern Med 2010;170:772778.
27. Kim, JW, Lee, KL, Jeong, JB, et al. Proton pump inhibitors as a risk factor for recurrence of Clostridium difficile-associated diarrhea. World J Gastroenterol 2010;16:35733577.
28. Jung, KS, Park, JJ, Chon, YE, et al. Risk Factors for treatment failure and recurrence after metronidazole treatment for Clostridium difficile-associated diarrhea. Gut Liver 2010;4:332337.
29. Cadena, J, Thompson, GR 3rd, Patterson, JE, et al. Clinical predictors and risk factors for relapsing Clostridium difficile infection. Am J Med Sci 2010;339:350355.
30. Garey, KW, Jiang, ZD, Ghantoji, S, Tam, VH, Arora, V, Dupont, HL. A common polymorphism in the interleukin-8 gene promoter is associated with an increased risk for recurrent Clostridium difficile infection. Clin Infect Dis 2010;51:14061410.
31. Drekonja, DM, Amundson, WH, Decarolis, DD, Kuskowski, MA, Lederle, FA, Johnson, JR. Antimicrobial use and risk for recurrent Clostridium difficile infection. Am J Med 2011;124(1081):e1081e1087.
32. Choi, HK, Kim, KH, Lee, SH, Lee, SJ. Risk factors for recurrence of Clostridium difficile infection: effect of vancomycin-resistant enterococci colonization. J Korean Med Sci 2011;26:859864.
33. Bauer, MP, Notermans, DW, van Benthem, BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011;377:6373.
34. Im, GY, Modayil, RJ, Lin, CT, et al. The appendix may protect against Clostridium difficile recurrence. Clin Gastroenterol Hepatol 2011;9:10721077.
35. Shakov, R, Salazar, RS, Kagunye, SK, Baddoura, WJ, DeBari, VA. Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting. Am J Infect Control 2011;39:194198.
36. Kim, YG, Graham, DY, Jang, BI. Proton pump inhibitor use and recurrent Clostridium difficile-associated disease: a case-control analysis matched by propensity score. J Clin Gastroenterol 2012;46:397400.
37. Eyre, DW, Walker, AS, Wyllie, D, et al. Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 2012;55(Suppl 2):S77S87.
38. Ryu, HS, Kim, YS, Seo, GS, Lee, YM, Choi, SC. Risk factors for recurrent Clostridium difficile infection. Intestinal Res 2012;10:176182.
39. Khanna, S, Aronson, SL, Kammer, PP, Baddour, LM, Pardi, DS. Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study. Mayo Clin Proc 2012;87:636642.
40. Rotramel, A, Poritz, LS, Messaris, E, Berg, A, Stewart, DB. PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics. J Gastrointestinal Surg 2012;16:22672273.
41. Hebert, C, Du, H, Peterson, LR, Robicsek, A. Electronic health record-based detection of risk factors for Clostridium difficile infection relapse. Infect Control Hospital Epidemiol 2013;34:407414.
42. Lupse, M, Flonta, M, Cioara, A, Filipescu, I, Todor, N. Predictors of first recurrence in Clostridium difficile-associated disease. A study of 306 patients hospitalized in a Romanian tertiary referral center. JGLD 2013;22:397403.
43. Samie, AA, Traub, M, Bachmann, K, Kopischke, K, Theilmann, L. Risk factors for recurrence of Clostridium difficile-associated diarrhoea. Hepatogastroenterology 2013;60:13511354.
44. Stewart, DB, Berg, A, Hegarty, J. Predicting recurrence of C. difficile colitis using bacterial virulence factors: binary toxin is the key. J Gastrointest Surg 2013;17:118124.
45. Rodriguez-Pardo, D, Almirante, B, Bartolome, RM, et al. Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain. J Clin Microbiol 2013;51:14651473.
46. Fujii, L, Fasolino, J, Crowell, MD, DiBaise, JK. Appendectomy and risk of Clostridium difficile recurrence. Infect Dis Clin Pract 2013;21:2832.
47. Lavergne, V, Beausejour, Y, Pichette, G, Ghannoum, M, Su, SH. Lymphopenia as a novel marker of Clostridium difficile infection recurrence. J Infect 2013;66:129135.
48. Freedberg, DE, Salmasian, H, Friedman, C, Abrams, JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013;108:17941801.
49. Louie, TJ, Miller, MA, Crook, DW, et al. Effect of age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc 2013;61:222230.
50. Zilberberg, MD, Reske, K, Olsen, M, Yan, Y, Dubberke, ER. Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study. BMC Infect Dis 2014;14:306.
51. Ramanathan, S, Johnson, S, Burns, SP, et al. Recurrence of Clostridium difficile infection among veterans with spinal cord injury and disorder. Am J Infect Control 2014;42:168173.
Type Description Title
WORD
Supplementary materials

Deshpande supplementary material
Appendix

 Word (564 KB)
564 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed